Advertisement
A vs MTD
Which Stock Would AI Choose? Agilent Technologies (A) vs. Mettler-Toledo International (MTD) Stock Comparison
Key Takeaways
- Agilent Technologies (A) and Mettler-Toledo International (MTD) both operate in the diagnostics and research segment of the healthcare sector, offering analytical and precision instruments.
- Recent market activity shows A with a year-to-date return of approximately 15% outperforming the S&P 500 benchmark, while MTD reported solid first-quarter results and raised full-year guidance.
- A is scheduled to release second-quarter fiscal 2026 results on May 27, 2026, following first-quarter revenue growth and an increased outlook.
- MTD posted first-quarter 2026 sales of $947 million with adjusted earnings per share of $8.91 and raised its full-year adjusted EPS guidance to a range of $46.30–$46.95.
- Both stocks have experienced volatility in recent weeks, with MTD trading near 52-week lows amid broader market pressures despite earnings beats.
- Sector exposure to life sciences and biopharma end-markets provides shared growth drivers, though differences in scale, product focus, and geographic reach create distinct risk profiles.
Introduction
Agilent Technologies (A) and Mettler-Toledo International (MTD) are established players in the precision instruments and diagnostics space, making them relevant for investors seeking exposure to healthcare technology and laboratory equipment markets. This comparison examines their business models, recent performance trends, and market positioning to assist traders and long-term investors evaluating relative opportunities within the sector. The analysis draws on observable financial metrics and developments to highlight contrasts in momentum and stability without forward-looking speculation.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent market activity, the stock has shown resilience with a year-to-date return exceeding the broader market benchmark. First-quarter fiscal 2026 results delivered revenue of $1.80 billion, reflecting reported growth of 7.0% and core growth of 4.4%, alongside raised full-year guidance. The company also declared a quarterly dividend. Upcoming second-quarter results on May 27, 2026, represent a near-term catalyst that could influence sentiment. Performance in recent weeks has featured modest fluctuations amid sector rotation and macroeconomic factors affecting laboratory spending.
Mettler-Toledo International (MTD) Overview and Recent Performance
Mettler-Toledo International (MTD) specializes in precision instruments and services for laboratory, industrial, and food retail applications, with a strong emphasis on weighing, analytical, and inspection solutions. Recent performance reflects first-quarter 2026 results showing sales of $947 million, up 7% reported and 3% in local currency, with adjusted earnings per share rising to $8.91. Management raised full-year adjusted EPS guidance to $46.30–$46.95. The stock traded near 52-week lows in recent weeks following earnings amid broader market headwinds, though it has stabilized around current levels near $1,100. Geographic and end-market diversification continues to support operational consistency.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the highest-performing AI trading bots suited to prevailing market conditions from a roster of hundreds of bots that cover thousands of tickers. These bots employ varied strategies, timeframes, and performance profiles across equities, with available statistics typically including win rates, profit factors, and drawdown metrics that range widely depending on the specific bot and market environment. Only those demonstrating consistent results and alignment with current trends are featured in the trending section. Review the full selection of AI trading bots and their detailed statistics on the Trending AI Robots page for additional context.
Head-to-Head Comparison
Agilent Technologies (A) and Mettler-Toledo International (MTD) share exposure to life sciences and laboratory end-markets but differ in scale and focus. A maintains a broader portfolio spanning diagnostics and applied markets with a larger market capitalization near $32 billion, while MTD emphasizes precision weighing and industrial applications with a market capitalization around $22 billion. Recent momentum favors A on a year-to-date basis, whereas MTD delivered stronger reported sales growth in its latest quarter and raised guidance. Risk factors include sensitivity to capital expenditure cycles for both, with MTD facing additional pressure from industrial demand variability. Market sentiment has been mixed, with earnings reactions driving short-term price swings in recent weeks.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, guidance revisions, and relative price stability in recent market activity, Tickeron’s AI models would currently assign a higher probabilistic weighting to Mettler-Toledo International (MTD). The company’s first-quarter beat and raised full-year outlook provide a clearer near-term catalyst profile compared with Agilent Technologies (A)’s upcoming earnings release, though both stocks remain subject to sector-wide variables that could alter this assessment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and MTD is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 3 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 6 bearish.
- MTD’s TA Score: 3 bullish, 7 bearish.
Price Growth
A (@Medical Specialties) experienced а -6.37% price change this week, while MTD (@Medical Specialties) price change was -3.32% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.49%. For the same industry, the average monthly price growth was +16.29%, and the average quarterly price growth was -4.45%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
MTD is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical Specialties (-3.49% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | MTD | A / MTD | |
| Capitalization | 36.6B | 23.1B | 158% |
| EBITDA | 1.96B | 1.25B | 156% |
| Gain YTD | -4.404 | -18.142 | 24% |
| P/E Ratio | 26.01 | 26.81 | 97% |
| Revenue | 7.23B | 4.09B | 177% |
| Total Cash | 1.81B | 60.6M | 2,982% |
| Total Debt | 3.36B | 2.23B | 151% |
A | MTD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 99 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | |
SMR RATING 1..100 | 44 | 2 | |
PRICE GROWTH RATING 1..100 | 43 | 58 | |
P/E GROWTH RATING 1..100 | 64 | 61 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is significantly better than the same rating for MTD (99) in the Medical Specialties industry. This means that A’s stock grew significantly faster than MTD’s over the last 12 months.
A's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as MTD (100) in the Medical Specialties industry. This means that A’s stock grew similarly to MTD’s over the last 12 months.
MTD's SMR Rating (2) in the Medical Specialties industry is somewhat better than the same rating for A (44) in the Biotechnology industry. This means that MTD’s stock grew somewhat faster than A’s over the last 12 months.
A's Price Growth Rating (43) in the Biotechnology industry is in the same range as MTD (58) in the Medical Specialties industry. This means that A’s stock grew similarly to MTD’s over the last 12 months.
MTD's P/E Growth Rating (61) in the Medical Specialties industry is in the same range as A (64) in the Biotechnology industry. This means that MTD’s stock grew similarly to A’s over the last 12 months.
| A | MTD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 65% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 60% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 64% |
| TrendMonth ODDS (%) | 1 day ago 58% | 1 day ago 59% |
| Advances ODDS (%) | 9 days ago 60% | 12 days ago 61% |
| Declines ODDS (%) | 1 day ago 62% | 5 days ago 65% |
| BollingerBands ODDS (%) | 1 day ago 63% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 69% | 1 day ago 56% |
Advertisement